Antiretroviral therapy-associated hyperlipidaemia in HIV disease

Current Opinion in Lipidology

Volumn 12, Issue 3, 2001, Pages 313-319

  Mooser, Vincent ^a   Carr, Andrew ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN; ZALCITABINE; ZIDOVUDINE;

ADIPOCYTE; CARDIOVASCULAR RISK; DISEASE SEVERITY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER CELL; NUTRITIONAL STATUS; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ADIPOCYTES; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYSTEINE ENDOPEPTIDASES; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIVER; MODELS, BIOLOGICAL; MULTIENZYME COMPLEXES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 0034991325     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200106000-00011     Document Type: Review

References (51)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
3. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
4. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
5. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
6. Hypertriglyceridemia in the acquired immunodeficiency syndrome
7. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
8. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B
9. Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome
10. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
11. Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor- to an efavirenz-containing regimen
12. Effect of ritonavir on lipids and post-heparin lipase activity in normal subjects
13. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
14. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
15. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
16. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. A 5-year cohort study
17. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
18. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants
19. HIV protease inhibitors stimulate hepatic triglyceride synthesis
20. HIV protease inhibitor-induced hyperlipidemia and lipodystrophy is mediated through regulation of sterol responsive element binding protein (SREBP) responsive genes
21. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
22. Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice
23. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice
24. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1
25. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets
26. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes
27. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia
28. Stimulation of vitamin A1 acid signaling by the HIV protease inhibitor indinavir
29. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta
30. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidemia and steroid hormone alterations
31. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
32. Lipodystrophies
33. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy
34. Life without white fat: A transgenic mouse
35. ADD1: A novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation
36. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis
37. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
38. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice
39. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus
40. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARg/RXR heterodimers
41. Inhibition of adipocyte differentiation by HIV protease inhibitors
42. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
43. ApoE genotype and protease-inhibitor-associated hyperlipidaemia
44. Vascular complications associated with the use of HIV protease inhibitors
45. Vascular complications associated with the use of HIV protease inhibitors
46. Vascular complications associated with the use of HIV protease inhibitors
47. Severe premature coronary artery disease with protease inhibitors
48. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients?
49. Premature atherosclerosis in HIV-infected individuals: Focus on protease inhibitor therapy
50. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
51. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group